Eli Lilly and Company (ETR: LLY)
Germany
· Delayed Price · Currency is EUR | Market Cap | 663.66B |
| Revenue (ttm) | 36.64B |
| Net Income (ttm) | 7.50B |
| Shares Out | n/a |
| EPS (ttm) | 8.29 |
| PE Ratio | 88.44 |
| Forward PE | n/a |
| Dividend | 4.82 (0.63%) |
| Ex-Dividend Date | Feb 14, 2025 |
| Volume | 20,225 |
| Open | 728.50 |
| Previous Close | 730.70 |
| Day's Range | 720.90 - 821.00 |
| 52-Week Range | 515.00 - 885.30 |
| Beta | 0.42 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jan 31, 2025 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the comp... [Read more]
Financial Performance
In 2023, Eli Lilly and Company's revenue was $34.12 billion, an increase of 19.56% compared to the previous year's $28.54 billion. Earnings were $5.24 billion, a decrease of -16.08%.
Financial numbers in USD Financial StatementsNews
FDA approves weight-loss drug to treat sleep apnea
The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the disorder affecting millions of Americans. On Friday, the federal agency gre...
Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?
Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea.
Eli Lilly given green light in US to treat sleep disorder with weight-loss drug
Regulatory go-ahead marks latest boost for drugmaker’s blockbuster anti-obesity franchise
Zepbound Approved For Sleep Apnea
The Food and Drug Administration approved Zepbound as the first prescription medicine to treat sleep apnea on Friday—marking a significant win for the drug company Eli Lilly, which had Zepbound approv...
Eli Lilly's Zepbound gains sleep apnea indication
Eli Lilly's Zepbound is now approved for obstructive sleep apnea. Read more here.
FDA approves weight loss drug Zepbound for sleep apnea
Zepbound, Eli Lilly’s weight loss drug, can now be used to treat obstructive sleep apnea in adults with obesity, the FDA said.
Lilly's weight-loss drug Zepbound wins US FDA approval for sleep apnea
The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to directly treat patients with...
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
The agency's decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.
FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity
Averaging up to 20% of weight loss, adults taking Zepbound had at least 25 fewer breathing interruptions each hour as they slept Up to 50% of adults taking Zepbound no longer had symptoms associated w...
FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity
Averaging up to 20% of weight loss, adults taking Zepbound had at least 25 fewer breathing interruptions each hour as they slept Up to 50% of adults taking Zepbound no longer had symptoms associated w...
What's Going On With Amgen Stock On Friday?
On Friday, Novo Nordisk A/S (NYSE: NVO) released headline results from the REDEFINE 1 Phase 3 trial in the global REDEFINE program . When evaluating the effects of treatment if all people adhered to ...
Stocks on the Move: Uber, Carmax, Novo Nordisk, Eli Lilly, Merck, Crown Castle and Accenture
The CNBC 'Halftime Report' Investment Committee discusses today's market movers.
Stocks on the Move: Uber, Carmax, Novo Nordisk, Eli Lilly, Merck, Crown Castle and Accenture
The CNBC 'Halftime Report' Investment Committee discusses todays market movers.
There's a New Obesity King
Eli Lilly is now comfortably ahead of Novo Nordisk in the race to dominate the market for obesity treatments.
Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now
The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. Tirzepatide's clinical trial updates were very positive this year, including the...
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up
Today's sell-off in Novo Nordisk may be the buying opportunity you've been waiting for.
Novo Nordisk's New Weight-Loss Drug Lags Behind Eli Lilly's Zepbound
Novo Nordisk's New Weight-Loss Drug Lags Behind Eli Lilly's Zepbound
Eli Lilly (LLY) Shares Surge Over 7% Amid Novo Nordisk's Trial Results
Eli Lilly (LLY) Shares Surge Over 7% Amid Novo Nordisk's Trial Results
Why is Novo Nordisk crashing after data for next-gen weight loss drug?
Novo Nordisk (NVO) stock plunges while Eli Lilly (LLY) gains as Danish drugmaker posts Phase 3 results for next-gen weight loss therapy, CagriSema. Find out why.
Healthcare stocks surge as tech faces headwinds: Today's market dynamics
Sector Overview: Divergent Paths in Tech and Healthcare The US stock market today presents a mixed landscape, with distinct trends observed across sectors. The technology and consumer cyclical sectors...
Lilly Cements Weight Loss Lead After Novo Trial Setback
Eli Lilly & Co. shares gained as its main rival in weight-loss drugs posted disappointing results from a clinical trial.
Indiana Sees $39 Billion Worth of Projects Under Construction, an Industrial Info News Alert
SUGAR LAND, Texas--(BUSINESS WIRE)--Thanks largely to some blockbuster projects, the value of industrial construction presently underway in Indiana and tracked by Industrial Info exceeds $39 billion. ...
Novo Nordisk’s new weight-loss drug works better, but not as well as expected
Novo Nordisk’s stock dives as new weight loss drug disappoints in a late-stage trial, which gave a boost to Eli Lilly shares.
Generic Drugs Threaten Market Share of Novo Nordisk (NVO) and Eli Lilly (LLY)
Generic Drugs Threaten Market Share of Novo Nordisk (NVO) and Eli Lilly (LLY)
Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump.
Novo Nordisk stock crashed Friday after the Danish giant reported its experimental obesity drug CagriSegma missed goals. Eli Lilly and Viking Therapeutics jumped